Referred to the Committee on Energy and Commerce, and in addition to the Committees on Education and Workforce, and Ways and Means, for a period to be subsequently determined by t…
The Capping Prescription Costs Act of 2025 caps annual patient cost-sharing for prescription drugs covered by health plans at $2,000 per individual and $4,000 per family in 2026, with future adjustments tied to the medical care component of CPI‑U. The cap applies to ACA qualified health plans and to group health plans by amending the Public Health Service Act, ERISA, and the Internal Revenue Code, effective for plan years beginning on or after January 1, 2026.
Left emphasizes affordability and adherence; right emphasizes cost-shifting and federal overreach.
Relative to its intended legislative type, this bill is a direct substantive policy change that establishes clear numeric caps on prescription drug cost-sharing and integrates those caps across the principal federal statutes that govern private and marketplace health plans.
The Capping Prescription Costs Act of 2025 caps annual patient cost-sharing for prescription drugs covered by health plans at $2,000 per individual and $4,000 per family in 2026, with future adjustments tied to the medical care component of CPI‑U.
The cap applies to ACA qualified health plans and to group health plans by amending the Public Health Service Act, ERISA, and the Internal Revenue Code, effective for plan years beginning on or after January 1, 2026.
Targeted, popular reform but meets organized industry resistance and higher Senate thresholds; missing cost offsets and details raise procedural obstacles.
Relative to its intended legislative type, this bill is a direct substantive policy change that establishes clear numeric caps on prescription drug cost-sharing and integrates those caps across the principal federal statutes that govern private and marketplace health plans. It is precise about amounts, indexing, statutory placement, and effective date but contains limited operational detail on definitions, counting rules, enforcement, and fiscal effects.
Left emphasizes affordability and adherence; right emphasizes cost-shifting and federal overreach.
These are examples from the analysis, not a ranked list of the most-affected groups.
Left emphasizes affordability and adherence; right emphasizes cost-shifting and federal overreach.
Likely favorable: views the bill as a direct, near-term way to reduce out-of-pocket drug burden and improve medication access.
May press for stronger price controls and protections for low-income people, and will note possible premium effects as uncertain.
Generally supportive but cautious: accepts patient-protection rationale while wanting evidence on cost, employer impact, and offsets.
Would favor monitoring, a measured phase-in, and clarity on effects for small employers and premiums.
Likely opposed: frames the bill as federal overreach into employer-sponsored benefits with probable cost-shifting to premiums and reduced plan flexibility.
Prefers market-based or state-centered solutions instead of a federal mandate.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Targeted, popular reform but meets organized industry resistance and higher Senate thresholds; missing cost offsets and details raise procedural obstacles.
The bill has not accumulated any surfaced votes yet.
Left emphasizes affordability and adherence; right emphasizes cost-shifting and federal overreach.
Targeted, popular reform but meets organized industry resistance and higher Senate thresholds; missing cost offsets and details raise proce…
Relative to its intended legislative type, this bill is a direct substantive policy change that establishes clear numeric caps on prescription drug cost-sharing and integrates those caps across the principal federal sta…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.